Stockreport

Nuvation Bio Inc. (NUVB) Amends Protocol on Safusidenib Trials in Astrocytoma [Yahoo! Finance]

Nuvation Bio Inc. Class A  (NUVB) 
PDF amendment to an ongoing global SIGMA study of safusidenib. The company is evaluating the efficacy and safety of safusidenib in patients with high-risk or high-grade IDH1 [Read more]